EA033373B1 - Композиции на водной основе, предварительно наполненный шприц, их применения и способ доставки гипофукозилированного или нефукозилированного антитела против baffr млекопитающему - Google Patents
Композиции на водной основе, предварительно наполненный шприц, их применения и способ доставки гипофукозилированного или нефукозилированного антитела против baffr млекопитающемуInfo
- Publication number
- EA033373B1 EA033373B1 EA201492292A EA201492292A EA033373B1 EA 033373 B1 EA033373 B1 EA 033373B1 EA 201492292 A EA201492292 A EA 201492292A EA 201492292 A EA201492292 A EA 201492292A EA 033373 B1 EA033373 B1 EA 033373B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- hypofucosylated
- mammal
- filled syringe
- delivering
- aqueous compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Изобретение относится к композициям на водной основе с pH 5,5-6,5, которые содержат гипофукозилированное или нефукозилированное антитело против BAFFR, сахарозу, гистидин, полисорбат 20 и аргинин в различных концентрациях. Кроме того, предложены предварительно наполненный шприц, включающий указанную композицию, и способ доставки гипофукозилированного или нефукозилированного антитела против BAFFR млекопитающему, включающий стадию введения млекопитающему такой композиции. Также представлены применения композиции или предварительно наполненного шприца для лечения заболевания или нарушения, которое опосредуется рецептором BAFF или лечение которого можно осуществлять посредством уничтожения или истощения В-клеток.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261658472P | 2012-06-12 | 2012-06-12 | |
PCT/IB2013/054777 WO2013186700A1 (en) | 2012-06-12 | 2013-06-11 | Antibody formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201492292A1 EA201492292A1 (ru) | 2015-04-30 |
EA033373B1 true EA033373B1 (ru) | 2019-10-31 |
Family
ID=48914378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201492292A EA033373B1 (ru) | 2012-06-12 | 2013-06-11 | Композиции на водной основе, предварительно наполненный шприц, их применения и способ доставки гипофукозилированного или нефукозилированного антитела против baffr млекопитающему |
Country Status (36)
Country | Link |
---|---|
US (4) | US9216219B2 (ru) |
EP (2) | EP3593814A1 (ru) |
JP (1) | JP6265978B2 (ru) |
KR (1) | KR102124820B1 (ru) |
CN (1) | CN104363920B (ru) |
AR (1) | AR091413A1 (ru) |
AU (1) | AU2013276112B2 (ru) |
BR (1) | BR112014030820B1 (ru) |
CA (1) | CA2875386C (ru) |
CL (1) | CL2014003370A1 (ru) |
CO (1) | CO7151487A2 (ru) |
CY (1) | CY1122181T1 (ru) |
DK (1) | DK2858671T3 (ru) |
EA (1) | EA033373B1 (ru) |
EC (1) | ECSP15017314A (ru) |
ES (1) | ES2751659T3 (ru) |
GT (1) | GT201400285A (ru) |
HK (1) | HK1203146A1 (ru) |
HR (1) | HRP20191827T1 (ru) |
HU (1) | HUE045523T2 (ru) |
IL (1) | IL235966B (ru) |
LT (1) | LT2858671T (ru) |
MA (1) | MA37616A1 (ru) |
MX (1) | MX363380B (ru) |
MY (1) | MY179818A (ru) |
NZ (1) | NZ630885A (ru) |
PE (1) | PE20150200A1 (ru) |
PH (1) | PH12014502778A1 (ru) |
PL (1) | PL2858671T3 (ru) |
PT (1) | PT2858671T (ru) |
SG (1) | SG11201408174UA (ru) |
SI (1) | SI2858671T1 (ru) |
TN (1) | TN2014000488A1 (ru) |
TW (1) | TWI653983B (ru) |
WO (1) | WO2013186700A1 (ru) |
ZA (1) | ZA201408547B (ru) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2521568T (lt) | 2010-01-06 | 2018-12-10 | Dyax Corp. | Plazmos kalikreiną surišantys baltymai |
EP2648750B1 (en) * | 2010-12-10 | 2017-01-25 | Novartis AG | Antibody formulation |
BR112013017080A8 (pt) | 2011-01-06 | 2023-05-09 | Dyax Corp | Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente |
US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
TWI660972B (zh) | 2012-09-10 | 2019-06-01 | 愛爾蘭商尼歐托普生物科學公司 | 抗mcam抗體及相關使用方法 |
EP3594244A1 (en) | 2013-03-15 | 2020-01-15 | Dyax Corp. | Anti-plasma kallikrein antibodies |
US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
CN104730237A (zh) * | 2013-12-23 | 2015-06-24 | 国家纳米科学中心 | 试纸及其应用以及检测甲胎蛋白抗原、乙肝表面抗原或HIV的gp41抗体的方法 |
KR20160131073A (ko) | 2014-03-12 | 2016-11-15 | 프로테나 바이오사이언시즈 리미티드 | Lg4-5에 대해 특이적인 항-라미닌4 항체 |
WO2015136469A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
KR101597037B1 (ko) | 2014-06-26 | 2016-02-24 | 엘지디스플레이 주식회사 | 구동소자의 전기적 특성 편차를 보상할 수 있는 유기발광 표시장치 |
US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
WO2016160926A1 (en) * | 2015-03-30 | 2016-10-06 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
WO2017046776A2 (en) * | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
PL3386541T3 (pl) * | 2015-12-07 | 2021-04-06 | Merck Patent Gmbh | Wodna formulacja farmaceutyczna zawierającą przeciwciało anty-pd-1 awelumab |
BR112018011622A2 (pt) | 2015-12-11 | 2018-11-27 | Dyax Corp | método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae |
CN108430507B (zh) * | 2015-12-18 | 2022-08-02 | 安斯泰来制药株式会社 | 含有抗人tslp受体抗体的药物组合物 |
JP6595132B2 (ja) * | 2016-06-16 | 2019-10-23 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Hivワクチン製剤 |
AU2017345454A1 (en) | 2016-10-19 | 2019-05-30 | Invenra Inc. | Antibody constructs |
MX2019007019A (es) | 2016-12-22 | 2019-08-16 | Univ Degli Studi Magna Graecia Catanzaro | Anticuerpo monoclonal dirigido a un epitope de cd43 sialoglicosilado especifico asociado al cancer. |
AU2018227036B2 (en) * | 2017-03-01 | 2021-07-08 | Medimmune Limited | Formulations of monoclonal antibodies |
US11639391B2 (en) * | 2017-04-18 | 2023-05-02 | Dr. Reddy's Laboratories Limited | Stable liquid pharmaceutical composition |
EP4218813A3 (en) | 2017-07-27 | 2023-08-16 | Alexion Pharmaceuticals, Inc. | High concentration anti-c5 antibody formulations |
SG11202001281WA (en) * | 2017-08-22 | 2020-03-30 | Biogen Ma Inc | Pharmaceutical compositions containing anti-beta amyloid antibodies |
EP3717512A4 (en) * | 2017-11-29 | 2021-08-25 | Prothena Biosciences Limited | LYOPHILIZED FORMULATION OF A MONOCLONAL ANTIBODY AGAINST TRANSTHYRETINE |
CN113227127A (zh) | 2018-06-05 | 2021-08-06 | 伦敦大学国王学院 | 向胃肠系统递送酬载的btnl3/8导引构建体 |
JOP20210152A1 (ar) | 2018-12-18 | 2023-01-30 | Novartis Ag | صياغة محلول بروتيني محتوية على تركيز عالٍ من جسم مضاد لـ vegf |
CR20210435A (es) | 2019-02-18 | 2021-09-20 | Lilly Co Eli | Formulación de anticuerpos terapéuticos |
TWI764097B (zh) * | 2019-02-26 | 2022-05-11 | 大陸商信達生物製藥(蘇州)有限公司 | 包含抗cd47抗體的製劑及其製備方法和用途 |
US20220356261A1 (en) | 2019-11-06 | 2022-11-10 | Novartis Ag | Treatment for sjögren's syndrome |
WO2021136274A1 (zh) * | 2019-12-30 | 2021-07-08 | 百奥泰生物制药股份有限公司 | 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用 |
CA3168600A1 (en) * | 2020-01-21 | 2021-07-29 | Innovent Biologics (Suzhou) Co., Ltd. | Recombinant fully human anti-tigit monoclonal antibody formulation, method for preparing same and use thereof |
CA3190678A1 (en) | 2020-08-04 | 2022-02-10 | Novartis Ag | Treatment of b cell malignancies |
CN115073598B (zh) * | 2021-03-15 | 2024-02-20 | 盛禾(中国)生物制药有限公司 | 一种抗baffr抗体及其应用 |
CN117203239A (zh) | 2021-05-04 | 2023-12-08 | 诺华股份有限公司 | 使用抗baffr抗体治疗系统性红斑狼疮 |
JP2024517796A (ja) | 2021-05-04 | 2024-04-23 | ノバルティス アーゲー | 抗baffr抗体を使用するループス腎炎の治療 |
KR20240069787A (ko) * | 2021-09-29 | 2024-05-20 | 드래곤플라이 쎄라퓨틱스, 인크. | 항체 표적화 baff-r 및 이의 사용 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060088523A1 (en) * | 2004-10-20 | 2006-04-27 | Genentech, Inc. | Antibody formulations |
WO2010007082A1 (en) * | 2008-07-17 | 2010-01-21 | Novartis Ag | Compositions and methods of use for therapeutic antibodies |
WO2012076670A2 (en) * | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US20020077461A1 (en) * | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
CA2375527A1 (en) | 1999-06-23 | 2000-12-28 | Oregon Health And Science University | Method for enhancing hematopoiesis |
AU7684201A (en) | 2000-06-28 | 2002-01-08 | Glycofi Inc | Methods for producing modified glycoproteins |
AU2002337935B2 (en) | 2001-10-25 | 2008-05-01 | Genentech, Inc. | Glycoprotein compositions |
PT1441589E (pt) | 2001-11-08 | 2012-08-13 | Abbott Biotherapeutics Corp | Formulação farmacêutica líquida estável de anticorpos igg |
EP3210624A1 (en) | 2002-02-27 | 2017-08-30 | Immunex Corporation | Stabilized tnfr-fc composition comprising arginine |
AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
AU2005323025A1 (en) * | 2004-12-31 | 2006-07-13 | Biogen Idec Ma Inc. | Polypeptides that bind BR3 and uses thereof |
KR101614983B1 (ko) * | 2009-11-17 | 2016-04-22 | 입센 파마 에스.에이.에스 | Hgh 및 rhigf―1의 조합물을 위한 제제 |
WO2013083497A1 (en) | 2011-12-06 | 2013-06-13 | F. Hoffmann-La Roche Ag | Antibody formulation |
US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
-
2013
- 2013-06-07 US US13/912,355 patent/US9216219B2/en active Active
- 2013-06-10 MA MA37616A patent/MA37616A1/fr unknown
- 2013-06-11 NZ NZ630885A patent/NZ630885A/en not_active IP Right Cessation
- 2013-06-11 DK DK13744818.9T patent/DK2858671T3/da active
- 2013-06-11 CN CN201380031181.8A patent/CN104363920B/zh active Active
- 2013-06-11 EP EP19185836.4A patent/EP3593814A1/en active Pending
- 2013-06-11 CA CA2875386A patent/CA2875386C/en active Active
- 2013-06-11 MX MX2014015262A patent/MX363380B/es unknown
- 2013-06-11 WO PCT/IB2013/054777 patent/WO2013186700A1/en active Application Filing
- 2013-06-11 SG SG11201408174UA patent/SG11201408174UA/en unknown
- 2013-06-11 TW TW102120795A patent/TWI653983B/zh active
- 2013-06-11 AU AU2013276112A patent/AU2013276112B2/en active Active
- 2013-06-11 LT LT13744818T patent/LT2858671T/lt unknown
- 2013-06-11 ES ES13744818T patent/ES2751659T3/es active Active
- 2013-06-11 BR BR112014030820-9A patent/BR112014030820B1/pt active IP Right Grant
- 2013-06-11 EP EP13744818.9A patent/EP2858671B1/en active Active
- 2013-06-11 PT PT137448189T patent/PT2858671T/pt unknown
- 2013-06-11 KR KR1020157000336A patent/KR102124820B1/ko active IP Right Grant
- 2013-06-11 SI SI201331596T patent/SI2858671T1/sl unknown
- 2013-06-11 PL PL13744818T patent/PL2858671T3/pl unknown
- 2013-06-11 EA EA201492292A patent/EA033373B1/ru not_active IP Right Cessation
- 2013-06-11 PE PE2014002437A patent/PE20150200A1/es not_active Application Discontinuation
- 2013-06-11 HU HUE13744818A patent/HUE045523T2/hu unknown
- 2013-06-11 MY MYPI2014703690A patent/MY179818A/en unknown
- 2013-06-11 JP JP2015516723A patent/JP6265978B2/ja active Active
- 2013-06-12 AR ARP130102057 patent/AR091413A1/es not_active Application Discontinuation
-
2014
- 2014-11-20 ZA ZA2014/08547A patent/ZA201408547B/en unknown
- 2014-11-21 TN TN2014000488A patent/TN2014000488A1/fr unknown
- 2014-11-27 IL IL235966A patent/IL235966B/en active IP Right Grant
- 2014-12-11 PH PH12014502778A patent/PH12014502778A1/en unknown
- 2014-12-11 CL CL2014003370A patent/CL2014003370A1/es unknown
- 2014-12-11 GT GT201400285A patent/GT201400285A/es unknown
- 2014-12-18 CO CO14278419A patent/CO7151487A2/es unknown
-
2015
- 2015-01-12 EC ECIEPI201517314A patent/ECSP15017314A/es unknown
- 2015-04-15 HK HK15103657.1A patent/HK1203146A1/xx unknown
- 2015-11-16 US US14/942,388 patent/US9751951B2/en active Active
-
2017
- 2017-08-31 US US15/692,490 patent/US20180051092A1/en not_active Abandoned
-
2018
- 2018-05-15 US US15/980,411 patent/US10689451B2/en active Active
-
2019
- 2019-10-09 HR HRP20191827TT patent/HRP20191827T1/hr unknown
- 2019-10-22 CY CY20191101096T patent/CY1122181T1/el unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060088523A1 (en) * | 2004-10-20 | 2006-04-27 | Genentech, Inc. | Antibody formulations |
WO2010007082A1 (en) * | 2008-07-17 | 2010-01-21 | Novartis Ag | Compositions and methods of use for therapeutic antibodies |
WO2012076670A2 (en) * | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
Non-Patent Citations (4)
Title |
---|
DAUGHERTY, A.L. ; MRSNY, R.J.: "Formulation and delivery issues for monoclonal antibody therapeutics", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 58, no. 5-6, 7 August 2006 (2006-08-07), AMSTERDAM, NL, pages 686 - 706, XP024892149, ISSN: 0169-409X, DOI: 10.1016/j.addr.2006.03.011 * |
FENG HE, SABINE HOGAN, RAMIL F. LATYPOV, LINDA O. NARHI, VLADIMIR I. RAZINKOV: "High Throughput Thermostability Screening of Monoclonal Antibody Formulations", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, US, vol. 99, no. 4, 1 April 2010 (2010-04-01), US, pages 1707 - 1720, XP007913147, ISSN: 0022-3549, DOI: 10.1002/jps.21955 * |
JAMES D. COLANDENE, LINDA M. MALDONADO, ALMA T. CREAGH, JOHN S. VRETTOS, KENNETH G. GOAD, THOMAS M. SPITZNAGEL: "Lyophilization cycle development for a high-concentration monoclonal antibody formulation lacking a crystalline bulking agent", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN CHEMICAL SOCIETY AND AMERICAN PHARMACEUTICAL ASSOCIATION, vol. 96, no. 6, 1 June 2007 (2007-06-01), pages 1598 - 1608, XP055083354, ISSN: 00223549, DOI: 10.1002/jps.20812 * |
WANG WEI: "Instability, stabilization, and formulation of liquid protein pharmaceuticals", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 185, no. 2, 20 August 1999 (1999-08-20), NL, pages 129 - 188, XP002323952, ISSN: 0378-5173, DOI: 10.1016/S0378-5173(99)00152-0 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA033373B1 (ru) | Композиции на водной основе, предварительно наполненный шприц, их применения и способ доставки гипофукозилированного или нефукозилированного антитела против baffr млекопитающему | |
EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
BR112014032699A2 (pt) | métodos de tratamento de síndrome metabólica pediátrica | |
EA201491161A1 (ru) | Фторированные модуляторы рецепторов эстрогенов и их применение | |
EA201270720A1 (ru) | Модуляторы рецептора андрогенов и их применение | |
WO2014004993A3 (en) | Methods of reducing ldl-p | |
NZ727516A (en) | Treatment of ocular neovascularization using a recombinant virus containing a nucleic acid encoding a vegf inhibitor | |
EA201270815A1 (ru) | Модуляторы рецепторов эстрогена и их применение | |
UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
EA201791916A1 (ru) | 2'-замещенные карбануклеозидные аналоги для противовирусного лечения | |
PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
EA201300669A1 (ru) | Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение | |
EA201590053A1 (ru) | Модуляторы пути системы комплемента и их применение | |
EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
EA201590655A8 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
EA201391581A1 (ru) | Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств | |
EA201400002A1 (ru) | Способы лечения заболеваний сетчатки | |
MX2018000352A (es) | 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b. | |
PH12014501937A1 (en) | Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative | |
MX2014004074A (es) | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. | |
EA201501054A1 (ru) | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы | |
EA201491937A1 (ru) | Инъецируемая композиция | |
EA201491702A1 (ru) | Оптимизированные терапевтические агенты для подкожного введения | |
TN2014000498A1 (en) | Pharmaceutical formulation | |
BRPI0907220A2 (pt) | métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |